What Meccellis Biotech does

Meccellis Biotech is a French privately-held medical device company founded in 2011/2012 and headquartered in La Rochelle, France, specializing in tissue and cell engineering with a focused portfolio of acellular dermal matrix (ADM) products derived from porcine dermis. The company operates as part of the Ph Tech Group alongside Apha Biomat and employs 11-50 people, manufacturing Class III biological matrices used in soft tissue repair across three primary surgical segments: breast reconstruction (CELLIS® Breast), digestive and general surgery including abdominal wall repair and hernia treatment (CELLIS®), and dental surgery (CELLIS® Dental). Two additional products are under development — CELLIS® Nac for nipple-areola complex reconstruction and CELLIS® Stoma 3D for parastomal hernia prevention — extending the addressable market within existing specialties.

The company's core technology rests on a proprietary tissue acellularization and purification process that preserves the natural three-dimensional structure of porcine dermis without chemical agents, combined with freeze-dry preservation technology enabling long-term shelf stability in sterile, preservative-free packaging. Meccellis generates revenue through one-time sales of its biological implants to hospitals, surgical centers, and surgeons via a sales-led go-to-market model that combines direct engagement with healthcare institutions and international distribution partnerships across 22+ countries. Pricing is not publicly disclosed but is positioned as "moderate" relative to competitor alternatives. The company invests significantly in clinical evidence — supporting 33 medical reviews and peer-reviewed publications — and engages surgeon specialists through a Scientific Committee to guide R&D and product development, with a 2022 Series B round of $8.25M earmarked partly for US market entry.

Geographically, Meccellis is primarily rooted in France and Europe, with a stated presence in 22-23+ countries and a deliberate US expansion funded out of the 2022 Series B. The leadership team is anchored by three associate-owners — CEO/R&D Director Anthony Pérés (UTC-trained biological engineer with 13 years at a leading surgical devices company), COO/General Director Guillaume Hofmanski (formerly a national product manager at an American medical devices company), and Deputy CEO/Marketing Director Aurélie Lammelin (CNAM-trained, formerly EMEA surgical training manager at a leading medical devices company). Capital structure includes long-term investor Océan Participations alongside Bpifrance, Volney Développement, Synergence BA, Fonds NACO, and Région Nouvelle-Aquitaine, with €91M in cumulative investment claimed by the company.

Name

Meccellis Biotech

Legal name

MECCELLIS BIOTECH

Website

https://meccellis.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Meccellis Biotech is a French privately-held medical device company that designs, manufactures, and commercializes acellular dermal matrix products derived from porcine dermis for soft tissue repair in breast reconstruction, digestive surgery, and dental procedures across 22+ countries.

Ownership category

akta.pro rank

Product category

Biological Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Acellular/Decellularized Matrices & ECM Products (HLAAAGAF)

Keywords

• Acellular dermal matrix
• Biological implants
• Soft tissue repair
• Porcine dermis matrix
• Medical device manufacturing

Headquarters

HQ city

La Rochelle

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Biological Implant Sales: Meccellis Biotech generates revenue through the sale of its acellular dermal matrix products (CELLIS®, CELLIS® Breast, CELLIS® Dental) to healthcare providers including hospitals, surgical centers, and surgeons. Products are sold as medical devices for use in soft tissue repair procedures.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Meccellis Biotech manufactures acellular dermal matrix (ADM) medical devices derived from porcine dermis for soft tissue repair. Its CELLIS® product line serves three surgical specialties: abdominal wall/digestive surgery (CELLIS®), breast reconstruction (CELLIS® Breast), and dental/oral surgery (CELLIS® Dental). Products use an exclusive tissue acellularization process that preserves natural dermal structure without chemical agents, combined with preservative-free freeze-dry packaging for long shelf-life.

Product overview

Meccellis Biotech is a French manufacturer of acellular dermal matrices (ADM) derived from porcine dermis. The CELLIS® product portfolio consists of three commercially available products (CELLIS® for abdominal wall/digestive surgery, CELLIS® Breast for breast reconstruction, and CELLIS® Dental for dental surgery) plus two products under development (CELLIS® Nac for nipple-areola complex reconstruction and CELLIS® Stoma 3D for parastomal hernia prevention). All products share the company's exclusive tissue acellularization process that preserves natural dermis structure without chemical agents, using freeze-dry technology for preservative-free long-term storage.

Differentiator

Problem solved

Functional benefit

Brands

• CELLIS®: Collagen matrix for soft tissue repair and abdominal wall reconstruction.
• CELLIS® Breast
• CELLIS® Dental
• CELLIS® Nac
• CELLIS® Stoma 3D

Products and services

• CELLIS® Collagen matrix derived from porcine dermis for soft tissue repair and abdominal wall reconstruction. Features exclusive acellularization process preserving natural dermis structure, preservative-free freeze-dry technology, and available in multiple sizes. Sold to general and digestive surgeons.
• CELLIS® Breast Acellular dermal matrix made from porcine dermis for breast reconstruction. Available in pocket and meshed configurations for sub-pectoral or pre-pectoral implant-based reconstruction, featuring quick preparation and flexible sizing. Used by plastic and reconstructive surgeons.
• CELLIS® Dental Class III medical device - cell-free, non-pyrogenic collagen membrane from porcine dermis for dental surgery. Used in implantology, periodontology, stomatology, and cranio-maxillo-facial surgery for soft tissue regeneration around teeth and implants.
• CELLIS® Nac 3D porcine dermal matrix for subcutaneous implantation in nipple-areola complex (NAC) reconstruction. Designed to provide nipple projection without skin flap technique. Currently under development, not yet CE marked.
• CELLIS® Stoma 3D Acellular dermal matrix with 3D funnel-shaped design for prevention of parastomal hernias following stoma creation. Designed to reinforce soft tissue and adapt to patient anatomy. Currently under development.

Quantifiable outcome

• MMPs level control enables proper biological implant integration during wound healing
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered minor and core.

• AquityminorOthersAquity is mentioned as a partner company, though the specific nature of the partnership is not detailed in the available sources.
• Prof. Laurent Lantieri (HEGP - Paris)coreStrategic or Co-development PartnerCollaboration with Prof. Laurent Lantieri, Head of Department at HEGP Paris, for the development of CELLIS Nac, an innovative biological matrix for nipple-areola complex reconstruction. Prof. Lantieri provides clinical expertise and guidance for product development.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AbbVie (Allergan Aesthetics — AlloDerm): AbbVie/Allergan markets AlloDerm, the pioneering acellular dermal matrix used across breast reconstruction, hernia repair, and dental surgery — the most established competitor to Meccellis's CELLIS® line globally, with deeper US distribution and longer clinical history.
• Coloplast: Coloplast's ostomy, hernia, and wound care portfolios include biologic mesh products used in parastomal hernia prevention and abdominal wall repair — directly overlapping with CELLIS® and CELLIS® Stoma 3D indications.
• Smith & Nephew: Smith & Nephew markets a broad portfolio of hernia and soft-tissue repair products including biologic grafts, with established surgical sales infrastructure across Europe and the US that overlaps Meccellis's target accounts.
• Baxter International: Baxter distributes biologic surgical implants and regenerative medicine products through its surgical solutions business, overlapping with Meccellis in hernia and soft-tissue reconstruction hospital channels.
• Becton Dickinson (BD): BD's surgical and biosciences segments include biologic grafts and hernia repair products, with global hospital sales reach that overlaps with Meccellis's distribution channels in 22+ countries.
• ConvaTec: ConvaTec's ostomy care and advanced wound care business provides biologic and synthetic matrices used in stoma care and parastomal hernia prevention — directly relevant to CELLIS® Stoma 3D and abdominal wall indications.

Direct peers

• MTF Biologics: MTF Biologics distributes a portfolio of allograft and xenograft dermal matrices used in breast reconstruction, complex hernia repair, and wound care — directly competing with Meccellis in the same porcine/bovine-derived ADM surgical indications across Europe and the US.
• Cook Medical (Biodesign): Cook Biotech's Biodesign line of biologic grafts (porcine small intestinal submucosa and similar platforms) competes head-to-head with CELLIS® in hernia, fistula, and soft-tissue repair, with comparable surgical-specialty sales motion.
• Integra LifeSciences: Integra LifeSciences offers dermal regeneration templates and wound matrices used in reconstructive surgery and burns — a direct adjacency to Meccellis's porcine ADM business with overlapping hospital channels and surgeon customers.

Emerging players

• Organogenesis: Organogenesis develops regenerative medicine and wound-care biologics (Apligraf, Dermagraft), with emerging adjacency to soft-tissue repair matrices relevant to Meccellis's wound and surgical applications.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/meccellis-biotech
• Facebookfacebook.com/Meccellis-biotech-365260720210012

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Meccellis Biotech